ClinicalTrials.gg
CompletedNCT04155918Updated Nov 19, 2020

Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

A Phase 2 interventional study of Group 1: AR882 Alone and in Combination with Febuxostat (FBX) and Group 2: AR882 Alone and in Combination with Allopurinol (ALLO) in Gout Patients, sponsored by Arthrosi Therapeutics. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-11-19.

Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2020, 6 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.

02

Conditions studied

  • Gout Patients

Browse trials for

Keywords

  • Hyperuricemia
  • Gout
  • URAT1
03

In context

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

This study's enrollment of 30 is below the median of 68 across 193 interventional studies indexed under Hyperuricemia.

Browse Hyperuricemia studies →

Lead sponsor

Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • History of gout
  • sUA > 7 mg/dL
  • Estimated (eGFR) ≥ 60 mL/min/1.73m2

Key Exclusion Criteria:

  • within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
  • History of cardiac abnormalities
  • Active peptic ulcer disease or active liver disease
  • History of kidney stones
  • Allergy or intolerance to colchicine, febuxostat, and allopurinol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    AR882/FBX

    Drug: Group 1: AR882 Alone and in Combination with Febuxostat (FBX)

  • Experimental
    AR882/ALLO

    Drug: Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)

Interventions

  • DrugGroup 1: AR882 Alone and in Combination with Febuxostat (FBX)

    AR882 + Febuxostat, AR882 alone, Febuxostat alone

    Also known as: Febuxostat (Adenuric®, Uloric®)

  • DrugGroup 2: AR882 Alone and in Combination with Allopurinol (ALLO)

    AR882 + Allopurinol, AR882 alone, Allopurinol alone

    Also known as: Allopurinol (Allosig®, Progout®, Zyloprim®)

06

What researchers measure

Primary outcomes

  1. PD profile of AR882 administered alone or in combination with febuxostat

    Profile from serum uric acid concentration over time

    Time frame: 22 Days

  2. PD profile of AR882 administered alone or in combination with allopurinol

    Profile from serum uric acid concentration over time.

    Time frame: 22 Days

  3. Serum uric acid (sUA) response rate

    sUA response rate to achieve sUA \<6, \<5, \<4, and \<3 mg/dL

    Time frame: 22 Days

Secondary outcomes

  1. Area under the curve (AUC) for plasma AR882

    Profile from plasma in terms of AUC for AR882

    Time frame: 22 Days

  2. Time to maximum plasma concentration (Tmax) for AR882

    Profile from plasma in terms of Tmax for AR882

    Time frame: 22 Days

  3. Maximum plasma concentration (Cmax) for AR882

    Profile from plasma in terms of Cmax for AR882

    Time frame: 22 Days

  4. Apparent terminal half-life (t1/2) for AR882

    Profile from plasma in terms of t1/2 for AR882

    Time frame: 22 Days

  5. Amount excreted (Ae) into urine for AR882

    Profile from urine in terms of Ae for AR882

    Time frame: 22 Days

  6. Renal clearance (CLr) for AR882

    Profile from urine in terms of CLr for AR882

    Time frame: 22 Days

  7. AUC for plasma for febuxostat

    Profile from plasma in terms of AUC for febuxostat

    Time frame: 22 Days

  8. Tmax for febuxostat

    Profile from plasma in terms of Tmax for febuxostat

    Time frame: 22 Days

  9. Cmax for febuxostat

    Profile from plasma in terms of Cmax for febuxostat

    Time frame: 22 Days

  10. t1/2 for febuxostat

    Profile from plasma in terms of t1/2 for febuxostat

    Time frame: 22 Days

  11. AUC for plasma allopurinol/oxypurinol

    Profile from plasma in terms of AUC for allopurinol/oxypurinol

    Time frame: 22 Days

  12. Tmax for allopurinol/oxypurinol

    Profile from plasma in terms of Tmax for allopurinol/oxypurinol

    Time frame: 22 Days

  13. Cmax for allopurinol/oxypurinol

    Profile from plasma in terms of Cmax for allopurinol/oxypurinol

    Time frame: 22 Days

  14. t1/2 for for allopurinol/oxypurinol

    Profile from plasma in terms of t1/2 for allopurinol/oxypurinol

    Time frame: 22 Days

  15. Ae in urine for allopurinol/oxypurinol

    Profile from urine in terms of Ae for allopurinol/oxypurinol

    Time frame: 22 Days

  16. CLr for allopurinol/oxypurinol

    Profile from urine in terms of CLr for allopurinol/oxypurinol

    Time frame: 22 Days

  17. AUC for plasma for colchicine

    Profile from plasma in terms of AUC for colchicine

    Time frame: 22 Days

  18. Tmax for colchicine

    Profile from plasma in terms of Tmax for colchicine

    Time frame: 22 Days

  19. Cmax for colchicine

    Profile from plasma in terms of Cmax for colchicine

    Time frame: 22 Days

  20. t1/2 for for colchicine

    Profile from plasma in terms of t1/2 for colchicine

    Time frame: 22 Days

  21. Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs

    Time frame: 28 Days

07

Study locations

1 site
  • Christchurch Clinical Studies Trust, Ltd (CCST)
    Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Sep 2020, 7 months.

Of 24 phase 2 interventional studies under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2019
First posted
Nov 7, 2019
StartActual
Feb 3, 2020
Primary completionActual
Sep 3, 2020
CompletionActual
Sep 3, 2020
Last update
Nov 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04155918
Responsible party
Sponsor
First posted
Nov 7, 2019
Start date
Feb 3, 2020
Primary completion
Sep 3, 2020
Completion
Sep 3, 2020
Last update
Nov 19, 2020

Study contacts

Christopher Wynne, MBChB, Grad Dip Pharm Med
principal investigator · Christchurch Clinical Studies Trust Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion